GSK Tykerb Opportunities Exist In Early Breast Cancer Setting – Oncologist
This article was originally published in The Pink Sheet Daily
Executive Summary
As many as 10 percent of early-stage HER2 positive breast cancer patients, who are not ideal candidates for Herceptin, could be candidates for Tykerb, oncologist Ellis estimates.
You may also be interested in...
GSK Exploring Tykerb Potential In Patients Not Previously Treated With Herceptin
Subset of breast cancer patients given lapatinib plus paclitaxel first line shows significant advantage in progression-free survival, duration of response.
GSK Exploring Tykerb Potential In Patients Not Previously Treated With Herceptin
Subset of breast cancer patients given lapatinib plus paclitaxel first line shows significant advantage in progression-free survival, duration of response.
GSK Patient Assistance Program Will Cover Newly Approved Tykerb
Tyrosine kinase inhibitor clears FDA March 13 for use in combination with Roche’s Xeloda for second-line treatment of advanced or metastatic HER2 positive breast cancer.